Procept Biorobotics (PRCT)

$51.08

-0.71

(-1.37%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Procept Biorobotics

  • Increasing Revenue

    Revenue is up for the last 15 quarters, 1.19M → 43.58M (in $), with an average increase of 21.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -24.62M → -27.50M (in $), with an average decrease of 11.7% per quarter

Performance

  • $50.98
    $53.93
    $51.08
    downward going graph

    0.2%

    Downside

    Day's Volatility :5.47%

    Upside

    5.28%

    downward going graph
  • $24.83
    $54.50
    $51.08
    downward going graph

    51.39%

    Downside

    52 Weeks Volatility :54.44%

    Upside

    6.28%

    downward going graph

Returns

PeriodProcept BioroboticsSector (Health Care)Index (Russel 2000)
3 Months
14.81%
-0.7%
0.0%
6 Months
83.85%
6.6%
0.0%
1 Year
39.9%
3.7%
-1.5%
3 Years
23.49%
14.0%
-21.8%

Highlights

Market Capitalization
2.6B
Book Value
$5.53
Earnings Per Share (EPS)
-2.24
Wall Street Target Price
58.57
Profit Margin
-77.76%
Operating Margin TTM
-67.82%
Return On Assets TTM
-19.11%
Return On Equity TTM
-44.33%
Revenue TTM
136.2M
Revenue Per Share TTM
2.88
Quarterly Revenue Growth YOY
83.3%
Gross Profit TTM
37.1M
EBITDA
-105.4M
Diluted Eps TTM
-2.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.0
EPS Estimate Next Year
-1.52
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
-0.52

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Procept Biorobotics(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 14.66%

Current $51.08
Target $58.57

Company Financials

FY19Y/Y Change
Revenue
6.2M
-
Net Income
-42.7M
-
Net Profit Margin
-691.41%
-
FY20Y/Y Change
Revenue
7.7M
↑ 25.09%
Net Income
-58.3M
↑ 36.58%
Net Profit Margin
-754.89%
↓ 63.48%
FY21Y/Y Change
Revenue
34.5M
↑ 346.72%
Net Income
-62.4M
↑ 7.09%
Net Profit Margin
-180.96%
↑ 573.93%
FY22Y/Y Change
Revenue
75.0M
↑ 117.6%
Net Income
-93.6M
↑ 50.01%
Net Profit Margin
-124.76%
↑ 56.2%
FY23Y/Y Change
Revenue
136.2M
↑ 81.55%
Net Income
-105.9M
↑ 13.16%
Net Profit Margin
-77.76%
↑ 47.0%
Q3 FY22Q/Q Change
Revenue
20.3M
↑ 21.92%
Net Income
-23.1M
↑ 12.82%
Net Profit Margin
-113.62%
↑ 9.16%
Q4 FY22Q/Q Change
Revenue
23.8M
↑ 16.85%
Net Income
-31.3M
↑ 35.39%
Net Profit Margin
-131.66%
↓ 18.04%
Q1 FY23Q/Q Change
Revenue
24.4M
↑ 2.64%
Net Income
-27.7M
↓ 11.5%
Net Profit Margin
-113.53%
↑ 18.13%
Q2 FY23Q/Q Change
Revenue
33.1M
↑ 35.65%
Net Income
-25.3M
↓ 8.73%
Net Profit Margin
-76.38%
↑ 37.15%
Q3 FY23Q/Q Change
Revenue
35.1M
↑ 6.04%
Net Income
-24.6M
↓ 2.62%
Net Profit Margin
-70.14%
↑ 6.24%
Q4 FY23Q/Q Change
Revenue
43.6M
↑ 24.16%
Net Income
-27.5M
↑ 11.7%
Net Profit Margin
-63.11%
↑ 7.03%
FY19Y/Y Change
Total Assets
62.0M
-
Total Liabilities
205.8M
-
FY20Y/Y Change
Total Assets
126.0M
↑ 103.2%
Total Liabilities
308.9M
↑ 50.06%
FY21Y/Y Change
Total Assets
337.0M
↑ 167.54%
Total Liabilities
69.9M
↓ 77.36%
FY22Y/Y Change
Total Assets
309.3M
↓ 8.22%
Total Liabilities
112.3M
↑ 60.52%
FY23Y/Y Change
Total Assets
404.7M
↑ 30.84%
Total Liabilities
124.0M
↑ 10.43%
Q3 FY22Q/Q Change
Total Assets
324.0M
↑ 4.22%
Total Liabilities
103.3M
↑ 43.96%
Q4 FY22Q/Q Change
Total Assets
309.3M
↓ 4.54%
Total Liabilities
112.3M
↑ 8.7%
Q1 FY23Q/Q Change
Total Assets
284.5M
↓ 8.04%
Total Liabilities
111.3M
↓ 0.82%
Q2 FY23Q/Q Change
Total Assets
272.4M
↓ 4.22%
Total Liabilities
116.5M
↑ 4.68%
Q3 FY23Q/Q Change
Total Assets
421.1M
↑ 54.57%
Total Liabilities
121.8M
↑ 4.48%
Q4 FY23Q/Q Change
Total Assets
404.7M
↓ 3.9%
Total Liabilities
124.0M
↑ 1.8%
FY19Y/Y Change
Operating Cash Flow
-43.8M
-
Investing Cash Flow
43.2M
-
Financing Cash Flow
26.5M
-
FY20Y/Y Change
Operating Cash Flow
-48.3M
↑ 10.33%
Investing Cash Flow
-233.0K
↓ 100.54%
Financing Cash Flow
106.8M
↑ 302.5%
FY21Y/Y Change
Operating Cash Flow
-57.3M
↑ 18.6%
Investing Cash Flow
-592.0K
↑ 154.08%
Financing Cash Flow
262.1M
↑ 145.49%
FY22Y/Y Change
Operating Cash Flow
-80.4M
↑ 40.2%
Investing Cash Flow
-2.7M
↑ 348.14%
Financing Cash Flow
3.6M
↓ 98.62%
Q3 FY22Q/Q Change
Operating Cash Flow
-19.9M
↑ 15.91%
Investing Cash Flow
-1.5M
↑ 594.5%
Financing Cash Flow
777.0K
↓ 72.85%
Q4 FY22Q/Q Change
Operating Cash Flow
-25.2M
↑ 26.81%
Investing Cash Flow
-866.0K
↓ 42.8%
Financing Cash Flow
-1.3M
↓ 269.63%
Q1 FY23Q/Q Change
Operating Cash Flow
-35.9M
↑ 42.72%
Investing Cash Flow
-5.3M
↑ 516.51%
Financing Cash Flow
380.0K
↓ 128.83%
Q2 FY23Q/Q Change
Operating Cash Flow
-28.3M
↓ 21.12%
Investing Cash Flow
-5.4M
↑ 0.62%
Financing Cash Flow
2.4M
↑ 539.47%

Technicals Summary

Sell

Neutral

Buy

Procept Biorobotics is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Procept Biorobotics
Procept Biorobotics
6.34%
83.85%
39.9%
23.49%
23.49%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Procept Biorobotics
Procept Biorobotics
53.06
NA
NA
-2.0
-0.44
-0.19
NA
5.53
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Procept Biorobotics
Procept Biorobotics
Buy
$2.6B
23.49%
53.06
-77.76%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • FMR Inc

    14.45%

  • Cpmg Inc

    10.46%

  • Vanguard Group Inc

    8.21%

  • T. Rowe Price Investment Management,Inc.

    7.25%

  • BlackRock Inc

    6.59%

  • AllianceBernstein L.P.

    4.03%

Company Information

based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.

Organization
Procept Biorobotics
Employees
626
CEO
Dr. Reza Zadno Ph.D.
Industry
Healthcare

Discover More

FAQs